Ward Hofhuis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ward Hofhuis has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Jurgen M. J. Piek
Department of Obstetrics and Gynecology and Catharina Cancer Institute Catharina Hospital Eindhoven The Netherlands
20 shared publications - Christianne A. R. Lok
Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands
19 shared publications - Cornelis D. de Kroon
Leiden University Medical Center, Leiden, The Netherlands
19 shared publications - Geertruid J. Brink
Department of Gynecologic Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
19 shared publications - Hans. W. Nijman
Department of Gynecology, University Medical Center Groningen, Groningen, The Netherlands
19 shared publications - Jolijn W. Groeneweg
Department of Gynecologic Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Drug screen response of CTRL+ cell line
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Drug screen response of CTRL+ cell line
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Methods S1 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Protocol cell culture and drug screen
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessMethods S1 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Protocol cell culture and drug screen
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Growth rate and passage number overview
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Growth rate and passage number overview
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Drug screen response of several locations per patient
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Drug screen response of several locations per patient
- Open Access
The Prognostic Value of FOXL2 Mutant Circulating Tumor DNA in Adult Granulosa Cell Tumor Patients
Objectives: The purpose of the study is to determine whether FOXL2 circulating tumor DNA can be used as a prognostic biomarker and marker for monitoring treatment response in patients with an adult-type granulosa cell tumor (aGCT). Methods: Plasma samples of patients included in the multicenter GRANULOSA study were collected before and after surgery for primary or recurrent aGCT, during follow-up, and during systemic treatment. The presence of ctDNA containing the FOXL2 402C>G mutation was analyzed in 284 samples from 20 primary and 34 recurrent aGCT patients, using digital droplet PCR. Clinical data were retrieved from electronic patient records, and patients were followed through January 2025. Results:FOXL2 mutant ctDNA was detected in 28 of 54 patients (48%). In primary aGCT, recurrences were more frequently seen in patients with detectable ctDNA (33% vs. 18%), and ctDNA remained detectable postoperatively in some cases despite complete cytoreduction. In recurrent aGCT patients, detectable ctDNA was associated with significantly worse overall survival (p = 0.023), and the postoperative presence of ctDNA following complete debulking surgery was significantly associated with a shorter recurrence-free survival (4.7 vs. 11.6 months, p = 0.025). Conclusions:FOXL2 mutant ctDNA could be a prognostic biomarker in aGCT, being associated with worse overall survival in recurrent aGCT patients. In addition, the presence of ctDNA after surgery could reflect the presence of minimal residual disease, negatively impacting the disease course. The implementation of FOXL2 ctDNA measurement in clinical practice may help to identify high-risk aGCT patients.
Open AccessThe Prognostic Value of FOXL2 Mutant Circulating Tumor DNA in Adult Granulosa Cell Tumor Patients
Objectives: The purpose of the study is to determine whether FOXL2 circulating tumor DNA can be used as a prognostic biomarker and marker for monitoring treatment response in patients with an adult-type granulosa cell tumor (aGCT). Methods: Plasma samples of patients included in the multicenter GRANULOSA study were collected before and after surgery for primary or recurrent aGCT, during follow-up, and during systemic treatment. The presence of ctDNA containing the FOXL2 402C>G mutation was analyzed in 284 samples from 20 primary and 34 recurrent aGCT patients, using digital droplet PCR. Clinical data were retrieved from electronic patient records, and patients were followed through January 2025. Results:FOXL2 mutant ctDNA was detected in 28 of 54 patients (48%). In primary aGCT, recurrences were more frequently seen in patients with detectable ctDNA (33% vs. 18%), and ctDNA remained detectable postoperatively in some cases despite complete cytoreduction. In recurrent aGCT patients, detectable ctDNA was associated with significantly worse overall survival (p = 0.023), and the postoperative presence of ctDNA following complete debulking surgery was significantly associated with a shorter recurrence-free survival (4.7 vs. 11.6 months, p = 0.025). Conclusions:FOXL2 mutant ctDNA could be a prognostic biomarker in aGCT, being associated with worse overall survival in recurrent aGCT patients. In addition, the presence of ctDNA after surgery could reflect the presence of minimal residual disease, negatively impacting the disease course. The implementation of FOXL2 ctDNA measurement in clinical practice may help to identify high-risk aGCT patients.
- Open Access
- 2 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Drug screen response of several locations per patient
- 2 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors
Drug screen response of several locations per patient